SEC Form 4 · accession 0000899243-17-008766
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lindsey Rolfe
Officer — See Remarks
Period of report
Mar 27, 2017
Accepted (ET)
Mar 28, 2017 · 6:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $68.31 | Mar 27, 2017 | A | 20,000 | A | — | Mar 27, 2027 | Common Stock | 20,000 | 20,000 | D |
| Restricted Stock UnitsF2,F3 | — | Mar 27, 2017 | A | 10,000 | A | — | — | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on March 1, 2018, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
- F2Each restricted stock unit represents the right to receive one share of Common Stock.
- F3The restricted stock units shall vest as to 25% of the units on March 1, 2018, and the remainder shall vest in substantially equal installments over the 12 quarters immediately following such date.
Remarks
Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance